2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168562
    σ1 Receptor ligand 1 98%
    σ1 Receptor ligand 1 (compound 5I) is a σ1 receptor ligand with a Ki of 3.9 nM. σ1 Receptor ligand 1 has a high plasma protein binding (89%) and promising metabolic stability in the presence of mouse liver microsomes and NADPH. σ1 Receptor ligand 1 can be utilized in neurological and cancer research.
    σ1 Receptor ligand 1
  • HY-168563
    BuChE-IN-15 98%
    BuChE-IN-15 (compound D12) is a selective BuChE/FAAH dual inhibitor with and show IC50 values of 81 and 400 nM for hBuChE and hFFAH, respectively. BuChE-IN-15 possesses good BBB penetration, and shows neuroprotection.BuChE-IN-15 can be used for study of Alzheimer.
    BuChE-IN-15
  • HY-168571
    BTF 98%
    BTF shows a selective binding affinity for OX1R with the Ki values of 2.33 nM and 62.8 nM of OX1R and OX2R, respectively.
    BTF
  • HY-168590
    MAO-B-IN-36 98%
    MAO-B-IN-36 (Compound A6) is a potent MAO-B inhibitor with an IC50 of 13 nM.
    MAO-B-IN-36
  • HY-168594
    α-Glucosidase/NLRP3-IN-1 98%
    α-Glucosidase/NLRP3-IN-1 (Compound 8) is a dual inhibitor of α-glucosidase and NLRP3, exhibiting an IC50 of 6.6 μM against α-glucosidase and inhibiting NLRP3 in multiple cell lines at a concentration of 100 μM. α-Glucosidase/NLRP3-IN-1 demonstrates neuroprotective and antidiabetic properties, and can be utilized in relevant research.
    α-Glucosidase/NLRP3-IN-1
  • HY-168603
    AChE/CA I-IN-1 98%
    AChE/CA I-IN-1 (Compound 2g) is the inhibitor for AChE and hCA I with Ki of 1.85 and 0.53 µM. AChE/CA I-IN-1 exhibits potential application in researches about Alzheimer's disease, glaucoma, and epilepsy.
    AChE/CA I-IN-1
  • HY-168622
    AChE-IN-79 98%
    AChE-IN-79 (compound 3i) is a AChE inhibitor with the IC50 of 2.7 µM and can be used for study of Alzheimer’s disease.
    AChE-IN-79
  • HY-168652
    4-PivO-NMT chloride 3019920-38-5 98%
    4-PivO-NMT chloride is an indole-derived AMPK signaling pathway modulator that regulates neurogenesis or neurite outgrowth by modulating AMPK activity. 4-PivO-NMT chloride holds promise for research in the fields of neurological disorders, pain, and inflammation.
    4-PivO-NMT chloride
  • HY-168728
    MAO-B-IN-37 894280-02-5 98%
    MAO-B-IN-37 (Compound 37) is a derivative of TT01001 (HY-114520), and a selective inhibitor for monoamine oxidase B (MAO-B) with an IC50 of 270 nM. MAO-B-IN-37 exhibits good metabolic stability in mice microsomes and good affinity with human serum albumin.
    MAO-B-IN-37
  • HY-168731
    AChE/BChE-IN-25 98%
    AChE/BChE-IN-25 (Compound 6e) is the orally active inhibitor for hAChE and eqBChE with IC50 of 7.9 nM and 0.79 nM. AChE/BChE-IN-25 exhibits antioxidant activity, that scavenges free radical with IC50 of 22.91 μM. AChE/BChE-IN-25 exhibits neuroprotective effects by reducing mitochondrial and cellular oxidative stress in the Drosophila Alzheimer's disease model. AChE/BChE-IN-25 ameliorates Scopolamine (HY-N0296)-induced spatial and cognitive memory impairment in mouse model.
    AChE/BChE-IN-25
  • HY-168742
    V1a/V2 antagonist 1 98%
    V1a/V2 antagonist 1 (Compound 18j) is an orally active dual V1a and V2 receptor antagonist with high binding affinity for both receptors (Ki: 0.13 nM for hV1a, 0.53 nM for hV2 and 0.5 nM for mV1a; IC50: 2.2 nM for hV1a). V1a/V2 antagonist 1 inhibits Oxytocin (HY-17571)-induced scratching behavior in mice.
    V1a/V2 antagonist 1
  • HY-168750
    MDMB-FUBICA 1971007-91-6 98%
    MDMB-FUBICA is a potent agonist of the cannabinoid receptors with psychoactive properties. MDMB-FUBICA can be used in the study of electronic cigarette.
    MDMB-FUBICA
  • HY-168771
    gamma-DGG TFA 71822-19-0 99.95%
    gamma-DGG TFA is the antagonist for excitatory amino acid, that blocks NMDA-(HY-17551), Kainate-(HY-N2309) and Quisqualate-(HY-12597) induced depolarization, and antagonises the excitatory postsynaptic potential (e.p.s.p.) in rat hippocampal slices.
    gamma-DGG TFA
  • HY-168825
    2-Methyl-α-pyrrolidinovalerophenone hydrochloride 850352-13-5 98%
    2-Methyl-α-pyrrolidinovalerophenone hydrochloride is a drug derivative.
    2-Methyl-α-pyrrolidinovalerophenone hydrochloride
  • HY-168831
    N-Propyl hexylone hydrochloride 27912-42-1 98%
    N-Propyl hexylone hydrochloride is a drug derivative.
    N-Propyl hexylone hydrochloride
  • HY-168835
    N,N-Diethyl hexylone hydrochloride 17763-17-6 98%
    N,N-Diethyl hexylone hydrochloride is a drug derivative.
    N,N-Diethyl hexylone hydrochloride
  • HY-168836
    1-[4-(Dimethylamino)phenyl]-2-[(phenylmethyl)amino]-1-propanone hydrochloride 2740524-43-8 98%
    1-[4-(Dimethylamino)phenyl]-2-[(phenylmethyl)amino]-1-propanone hydrochloride is a drug derivative.
    1-[4-(Dimethylamino)phenyl]-2-[(phenylmethyl)amino]-1-propanone hydrochloride
  • HY-168857
    GSK-3β inhibitor 24 3069913-37-4 98%
    GSK-3β inhibitor 24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects.
    GSK-3β inhibitor 24
  • HY-168859
    JNK3 inhibitor-9 98%
    JNK3 inhibitor-9 (Compound 24a) is a potent, selective and BBB-permeable JNK3 inhibitor with an IC50 value of 12 nM. JNK3 inhibitor-9 also potently inhibits GSK3α/β (IC50s: 14 and 35 nM, respectively) involved in Tau phosphorylation. JNK3 inhibitor-9 reduces c-Jun and APP phosphorylation. JNK3 inhibitor-9 protects neurons from Aβ1-42 toxicity.
    JNK3 inhibitor-9
  • HY-168966
    JNJ-54082730 2097493-39-3 98%
    JNJ-54082730 (Compound 1) is the orally active inhibitor for phosphodiesterase (PDE) that inhibits PDE2A, PDE3B, and PDE10A2 with IC50s of 0.95 nM, 6.17 μM (pIC50=5.21) and 87.1 nM (pIC50=7.06), respectively. JNJ-54082730 modulates the activity of AMPA receptor, enhance the synaptic plasticity and promotes the learning and memory function in rats models. JNJ-54082730 can cross blood-brain barrier.
    JNJ-54082730
Cat. No. Product Name / Synonyms Application Reactivity